See the DrugPatentWatch profile for aimovig
The cost of Aimovig (erenumab-aooe) without insurance can vary significantly depending on the pharmacy and any available discount programs. While specific prices are not publicly disclosed by the manufacturer, pricing information from various sources suggests that a single 140 mg injection can range from approximately $600 to over $700 [1].
What factors influence the price of Aimovig?
The price of Aimovig without insurance is influenced by several factors. These include the specific dosage administered, the number of injections prescribed, and the retail markup at different pharmacies. Additionally, the availability of manufacturer-sponsored patient assistance programs or third-party discount cards can impact the out-of-pocket cost for patients.
Are there ways to get Aimovig at a lower cost?
Patients seeking to reduce the cost of Aimovig without insurance may explore several options. These include inquiring about patient assistance programs offered by the manufacturer, which can provide financial support to eligible individuals. Looking into savings cards or coupons from pharmaceutical discount providers may also offer reduced prices. Comparing prices across different pharmacies can also lead to savings, as retail markups can differ.
When does Aimovig's patent expire?
The patent exclusivity for Aimovig is a critical factor in its pricing and the potential introduction of generic alternatives. According to DrugPatentWatch.com, the primary patents protecting Aimovig are set to expire in 2031 [2]. However, patent landscapes can be complex, and additional patents or legal challenges could influence the actual market entry of biosimilar or generic versions.
What are the alternatives to Aimovig for migraine prevention?
Several other medications are available for migraine prevention, offering alternatives to Aimovig. These include oral medications such as antidepressants (e.g., amitriptyline, nortriptyline) and anti-seizure drugs (e.g., topiramate, valproic acid), as well as beta-blockers (e.g., propranolol, metoprolol). Additionally, other injectable biologic treatments like Ajovy (fremanezumab-vfrm) and Emgality (galcanezumab-gnlm) are used for migraine prophylaxis [3]. The choice of alternative often depends on individual patient needs, medical history, and physician recommendations.
How do Aimovig and Emgality compare?
Aimovig and Emgality are both CGRP inhibitor medications used for migraine prevention, but they have some differences. Aimovig targets the calcitonin gene-related peptide (CGRP) receptor, while Emgality targets the CGRP ligand. Both are administered via subcutaneous injection, but Emgality offers both monthly and a quarterly dosing option for prevention [3]. Clinical trial data and physician experience guide the selection between these two agents, with efficacy and tolerability being key considerations.
What are the common side effects of Aimovig?
The most frequently reported side effects associated with Aimovig include injection site reactions, such as pain, redness, or itching. Other common adverse events reported in clinical trials were upper respiratory tract infections, flu-like symptoms, and back pain [1]. Patients experiencing severe or persistent side effects should consult their healthcare provider.
*
**Sources
1. GoodRx
2. DrugPatentWatch.com
3. National Library of Medicine